AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2026)

AbCellera Biologics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $642.5 million for Q1 2026.

• Quarterly Non-Current Assets rose 10.93% year-over-year to $642.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $642.5 million (up 10.93% YoY) and the FY2025 annual result came in at $628.7 million, up 3.21% from the prior year.
• Non-Current Assets was $642.5 million for Q1 2026 at AbCellera Biologics, up from $628.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $660.9 million in Q3 2025 and bottomed at $417.9 million in Q1 2022.
• A 5-year average of $587.2 million and a median of $609.2 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 89.49% — and 2025, when it retreated 10.77%.
• AbCellera Biologics' Non-Current Assets stood at $515.4 million in 2022, then increased by 19.54% to $616.1 million in 2023, then declined by 1.12% to $609.2 million in 2024, then increased by 3.21% to $628.7 million in 2025, then gained by 2.19% to $642.5 million in 2026.
• Business Quant data shows ABCL's Non-Current Assets at $642.5 million in Q1 2026, $628.7 million in Q4 2025, and $660.9 million in Q3 2025.